Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Nevada: below-average open trial sites
240 of 900 in-state trials are recruiting (27%); below the 37% national average by 10 percentage points.
According to ClinicalTrials.gov-derived indexes, Nevada sits in the lower half of US states by in-state trial count (#36 of 52 states by registered in-state trial count).
Nevada: 900 US clinical trials with in-state sites, 240 recruiting.
Nevada has 900 registered US clinical trials with a study site in-state, 240 of them currently recruiting (below the 37% national average by 10 percentage points). 263 of these trials are in Phase 3 (late-stage) and 265 in Phase 2. The most frequently studied condition in Nevada is Prostate Cancer, with 18 linked trials.
Thin-volume Nevada archive
Nevada open-enrollment share is 27% (p12 of states with sites; national baseline 37%). Treat this page as a compact local index (thin-volume · low-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Nevada still shows 240 recruiting of 900 in-state trials (27% open), but below the 37% national average by 10 percentage points, so archived statuses weigh heavier than the national baseline.
- 27%
- open (below national share)
- 240
- still recruiting despite cool share
- 265
- Phase 2 rows in this footprint
- 18
- top: Prostate Cancer
Recruiting share is below the 37% national average by 10 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Nevada vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
900 Top 69% more indexed trials than 31% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Nevada on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Nevada open-enrollment share sits below the national baseline.
240 of 900 in-state trials (26.7%) are recruiting, against 37% nationally (-10.3 percentage points). Counts include every study with at least one recorded site in the state.
-
Las Vegas dominates Nevada's trial geography.
Las Vegas lists 660 of 900 in-state trials (73.3%) across 367 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Prostate Cancer is the most-studied condition in Nevada.
18 of 900 in-state trials (2%) list Prostate Cancer. That is a local concentration figure, not a national disease ranking.
-
Nevada sponsorship is fragmented across many organizations.
Eli Lilly and Company appears on 32 of 900 in-state trials (3.6%). Sponsor identity is as filed on ClinicalTrials.gov.
-
445 Nevada trials carry a completed status.
445 of 900 (49.4%) are completed. The open share above is the remainder that still lists recruiting.
Where trials run in Nevada
Las Vegas carries 660 of Nevada's 900 indexed trials (73%) across 367 named sites, ahead of Reno at 156. 5 cities clear five listed trials, together naming 526 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Las Vegas | 660 | 367 |
| Reno | 156 | 93 |
| Henderson | 77 | 53 |
| Nellis Air Force Base | 14 | 5 |
| North Las Vegas | 10 | 8 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Nevada open-enrollment share is 27% (p12 of states with sites; national baseline 37%).
Nevada: open share sits in the low tercile of states
Geography is concentrated: Las Vegas alone accounts for 73% of Nevada's indexed trials (660 of 900), with Reno a distant second at 156.
Phase mix: 263 Phase 3 vs 265 Phase 2 (balanced across stages).
Top condition: Prostate Cancer (18 trials); top sponsor Eli Lilly and Company (32).
thin-volume · low-open figures (900 trials · 27% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Nevada on open-enrollment share
Cross-state peers under the open-share low read (thin-volume · low-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- Rhode Island · 753 trials · 34% recruiting
- Oklahoma · 1,061 trials · 34% recruiting
- Delaware · 652 trials · 33% recruiting
- New Mexico · 579 trials · 29% recruiting
- Nebraska · 1,301 trials · 29% recruiting
Similar low-open peers (± trial volume)
- Idaho · 26% recruiting · 633 trials
- Mississippi · 27% recruiting · 500 trials
- Louisiana · 28% recruiting · 1,936 trials
- Hawaii · 26% recruiting · 437 trials
- Alaska · 25% recruiting · 485 trials